Showing 1821-1830 of 6978 results for "".
Almirall/Allergan, LEO/Bayer Deals
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-almirall-allergan-leo-bayer-deals/18240/Leo Pharma has agreed to acquire Bayer's global prescription dermatology unit, and Almirall will acquire Allergan's US portfolio of medical dermatology drugs. When it comes to patient engagement, aesthetic practices often have the right mindset, but they may lack the skills or time necessary to execJuvederm Approved for Lips, CoolMini Applicator Cleared
https://practicaldermatology.com/topics/psoriasis/juvederm-approved-for-lips-coolmini-applicator-cleared/18828/In this edition, a look at Allergan's Juvederm Voluma XC approval for lips an Zeltiq's CoolMini applicator for treatment of the sub mental area. Plus, there's new data for secukinumab in psoriatic arthritis (PSA) and Kathleen Sebelius has joined the Board of Directors of Dermira.The Safety of New Systemics
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/the-safety-of-new-systemics/33159/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, provides an overview of the safey of systemic therapies such as JAK inhibitors and other similar drugs, giving dermatologists a high-level look at what they need to help clinical decision-making.Journal Club: Combination Therapy With Dupilumab and Upadacitinib
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-combination-therapy-with-dupilumab-and-upadacitinib/32408/Neal Bhatia, MD, FAAD, and Ted Lain, MD, MBA, FAAD, discuss the International Journal of Dermatology article “Combination Therapy With Upadacitinib and Dupilumab for Severe Atopic Dermatitis,” and their own experiences with similar treatment strategies.Treatment Breaks for Super Responders: An Update from the GUIDE Study of Guselkumab in Psoriasis
https://practicaldermatology.com/topics/psoriasis/treatment-breaks-for-super-responders-an-update-from-the-guide-study-of-guselkumab-in-psoriasis/20222/Knut Schäkel, MD, a dermatologist at Heidelberg University Hospital in Germany, shares data on the withdrawal stage of the GUIDE study of guselkumab (Tremfya) in moderate-to-severe plaque psoriasis from his talk at the 2023 European Academy of Dermatology and Venereology meeting in Berlin.An Updated, Holistic Approach to Managing Hyperpigmentation
https://practicaldermatology.com/topics/pigmentary-disorders/an-updated-holistic-approach-to-managing-hyperpigmentation/20102/As an early adopter of Cyspera, Suneel Chilukuri, MD has witnessed the evolution of the topical formulation. Cyspera Intensive System provides a three-step holistic approach to skincare that supports healthier, brighter skin within about four to six weeks.DermWireTV: Sanofi Genzyme & Regeneron Global AD Report; Hydroquinone; Pfizer NDA; VCS
https://practicaldermatology.com/topics/practice-management/dermwiretv-sanofi-genzyme-regeneron-global-ad-report-hydroquinone-pfizer-nda-vcs/19868/The “Improving Quality of Care in AD” report, commissioned and funded by Sanofi Genzyme & Regeneron and completed by KPMG, debuts at the annual meeting of the EADV. Changes to FDA regulations implemented as part of the CARES Act limit access to hydroquinone. This year’s Virtual Vegas Cosmetic SuQuarantine Quorum: Circling the Wagons
https://practicaldermatology.com/topics/practice-management/quarantine-quorum-circling-the-wagons/18180/With Quarantine Quorum, host Neal Bahtia, MD provides a diary of life during the COVID-19 pandemic, talking to members of the dermatology community as they adapt to ongoing changes in their personal and private lives. In this edition, Hilary Baldwin, MD; Adam J. Friedman, MD; Mark Kaufmann, MD; andBuyer Beware: CBD Products May Peddle False Hope Amid Corona Fears
https://practicaldermatology.com/series/dermatology-dispatches/buyer-beware-cbd-products-may-peddle-false-hope-amid-corona-fears/19775/Any claims that a medical cannabinoid-based product can kill COVID-19 are “absolutely unsubstantiated,” warns Adam Friedman, MD. There is no evidence that these products contain any antiviral properties, and patients should be advised against believing such claims.Advances in Tattoo Removal and More
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/advances-in-tattoo-removal-and-more/19756/Eric Bernstein, MD shares insights on the benefits of picosecond domain lasers for everything from rejuvenation to tattoo removal. He discusses his recent experience with the 730nm handpiece and its efficacy on multiple ink colors and all skin types. In addition, he talks about other new technologie